Levothyroxine BE Studies In Athyreotic Patients Would Be “Unrealistic” – FDA
Executive Summary
Levothyroxine bioequivalence studies in patients with no thyroid activity that also measure thyroid stimulating hormone would be "unrealistic," FDA said during the meeting of the Advisory Committee for Pharmaceutical Science March 13